Thyrocare Technologies Ltd

Thyrocare Technologies has allotted 10,61,07,794 equity shares of Rs 10 each under bonus issue in ratio of 2:1. Post allotment, the paid up equity share capital has increased to 15,91,61,691 equity shares of Rs 10 each. Powered by Capital Market - Live

Thyrocare Technologies announced that Nitin Chugh, Chief Commercial Officer and part of the Senior Management Personnel of the company has resigned with effect from 30 November 2025. Powered by Capital Market - Live

Docon Technologies Private Limited ('Docon'), Promoter of Thyrocare Technologies has sold 53,32,860 equity shares of the Company through market trades on 24th October 2025 for an aggregate gross consideration of Rs. 667.69 crore (rounded off), at an average price of approximately Rs. 1,252.03 per share (rounded off). The number of shares sold constitutes approximately 10% of the total paid-up capital of the Company. Following this transaction, Docon continues to be a promoter of the Company. Post this transaction, the promoter shareholding in the Company stands reduced to 60.93% from the pre-transaction shareholding of 70.98%.Powered by Capital Market - Live

Thyrocare Technologies has fixed 24 October 2025 as record date for interim dividend. Powered by Capital Market - Live

The Board of Thyrocare Technologies has approved issuance of bonus shares in the proportion of 2:1, i.e. 2 bonus equity shares of Rs 10 each for every 1 fully paid-up equity share held as on the record date. Also, the board has declared an interim dividend of INR 7 per equity share of the face value of Rs 10 each, pre-bonus issuancePowered by Capital Market - Live

Net profit of Thyrocare Technologies rose 79.94% to Rs 47.99 crore in the quarter ended September 2025 as against Rs 26.67 crore during the previous quarter ended September 2024. Sales rose 22.09% to Rs 216.53 crore in the quarter ended September 2025 as against Rs 177.36 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales216.53177.36 22 OPM %32.9527.06 - PBDT74.0949.85 49 PBT62.5836.78 70 NP47.9926.67 80 Powered by Capital Market - Live

Thyrocare Technologies announced that the Board of Directors of the Company at its meeting held on 14 October 2025, inter alia, have recommended the interim dividend of Rs 7 per equity Share (i.e. 70%) , subject to the approval of the shareholders.Powered by Capital Market - Live

In the Pathology business, franchise revenue grew by 20% year-on-year, while partnership revenue recorded a robust 35% year-on-year growth. Thyrocare processed 53.3 million tests in Q2FY26, marking a strong 21% year-on-year growth. Reported EBITDA improved by 48% to Rs 71.45 crore in Q2 FY26 from Rs 48.22 crore in Q2 FY25. Reported EBITDA for Q2 FY26 was 33% as against 27% in Q2 FY25. Profit before tax in Q2 FY26 stood at Rs 62.58 crore, up by 70% from Rs 36.78 crore in Q2 FY25. The company is debt-free on a consolidated basis and holds a net cash and cash equivalents including short-term investments of over Rs 190 crore. The company's board of directors has approved issuance of bonus shares in the proportion of 2:1, i.e. 2 bonus equity shares of Rs 10 each for every 1 fully paid-up equity share held as on the record date. The company will notify the record date for determining the eligibility of shareholders entitled to receive bonus shares in due course. The board of directors has declared an interim dividend of Rs 7 per equity share of the face value of Rs 10 each, pre-bonus issuance. The record date for the interim dividend payout will be 24 October 2025. Thyrocare Technologies is India's first and foremost advanced fully automated laboratory chain with strong presence PAN India. The company focuses on providing quality and affordable diagnostic services to laboratories and hospitals. Thyrocare has a quarterly active franchise count of more than 10,000 and has processed over 53.3 million diagnostic and screening investigations in Q2 FY26. The scrip had gained 0.12% to end at Rs 1264.60 on the BSE today. Powered by Capital Market - Live

Thyrocare Technologies will hold a meeting of the Board of Directors of the Company on 14 October 2025.Powered by Capital Market - Live

Thyrocare Technologies announced that as part of the ongoing leadership development across the group, the company has received an intimation dated 06 August 2025 from API Holdings (API), the ultimate holding company of Thyrocare, stating that  the Board of Directors of API has approved the appointment of Rahul Guha, Managing Director and Chief Executive Officer of Thyrocare, with the additional responsibility of Managing Director and Chief Executive Officer of API, with effect from 27 August  2025. Prior to this, Guha was serving as President - Operations at API and KMP, focusing on driving synergies across API and its group companies. Powered by Capital Market - Live